
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

